Tsuda H, Hirohashi S, Shimosato Y, Tanaka Y, Hirota T, Tsugane S, Shiraishi M, Toyoshima K, Yamamoto T, Terada M
Pathology Division, National Cancer Center Research Institute, Tokyo.
Jpn J Cancer Res. 1990 Apr;81(4):327-32. doi: 10.1111/j.1349-7006.1990.tb02571.x.
Using a polyclonal antibody monospecific to the c-erbB-2 oncogene product, an immunohistochemical study on the expression of c-erbB-2 protein was performed in formalin-fixed, paraffin-embedded tissue sections from 176 primary breast carcinomas in which amplification of the c-erbB-2 gene had been detected in 28 cases. Expression of the c-erbB-2 protein was detected in 44 cases (25%), being strongly positive in 27 (15%) and weakly positive in 17 (10%). All cases with amplification of c-erbB-2 showed positive staining of its protein. There were only four cases in which c-erbB-2 was strongly expressed without amplification of the gene. In the group showing strongly positive staining, both overall and disease-free survival were significantly poorer than in the remainder of the cases. Using Cox's regression model analysis, overexpression of c-erbB-2 protein was demonstrated to be an effective prognostic factor independent of nodal status or tumor size.
使用一种对c-erbB-2癌基因产物具有单特异性的多克隆抗体，对176例原发性乳腺癌的福尔马林固定、石蜡包埋组织切片进行了c-erbB-2蛋白表达的免疫组织化学研究，其中28例检测到c-erbB-2基因扩增。在44例（25%）中检测到c-erbB-2蛋白表达，27例（15%）为强阳性，17例（10%）为弱阳性。所有c-erbB-2扩增的病例其蛋白染色均为阳性。仅有4例c-erbB-2强表达而基因未扩增。在强阳性染色组中，总生存率和无病生存率均显著低于其余病例。使用Cox回归模型分析表明，c-erbB-2蛋白的过表达是一个独立于淋巴结状态或肿瘤大小的有效预后因素。
